Dexmethylphenidate
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Healthy Volunteers in Fed and Fasted State
Conditions
Healthy Volunteers in Fed and Fasted State
Trial Timeline
Oct 31, 2024 → Dec 27, 2024
NCT ID
NCT07119073About Dexmethylphenidate
Dexmethylphenidate is a phase 1 stage product being developed by Cingulate for Healthy Volunteers in Fed and Fasted State. The current trial status is completed. This product is registered under clinical trial identifier NCT07119073. Target conditions include Healthy Volunteers in Fed and Fasted State.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07119073 | Phase 1 | Completed |
| NCT04449250 | Phase 1 | Completed |
Competing Products
20 competing products in Healthy Volunteers in Fed and Fasted State
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 33 |
| Valsartan | Novartis | Phase 1 | 33 |
| CSL112 + Placebo | CSL | Phase 1 | 32 |
| UT-15C | United Therapeutics | Phase 1 | 30 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 25 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 25 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 25 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 25 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 25 |
| TRV734 | Trevena | Phase 1 | 25 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 33 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 28 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 33 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 23 |
| LY2157299 | Eli Lilly | Phase 1 | 33 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 33 |
| LOXO-783 | Eli Lilly | Phase 1 | 33 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 33 |
Other Products from Cingulate
CTx-1301-Dexmethylphenidate 12.5 mg (titration only) + CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose) + PlaceboPhase 3
69
CTx-1301 - Dexmethylphenidate 6.25mg + CTx-1301 - Dexmethylphenidate 12.5mg + CTx-1301 - Dexmethylphenidate 18.75mg + CTx-1301 - Dexmethylphenidate 25.0mg + CTx-1301 - Dexmethylphenidate 31.25mg + CTx-1301 - Dexmethylphenidate 37.5mg + PlaceboPhase 3
69
CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg + CTx-1301 - Dexmethylphenidate 50mg + PlaceboPhase 3
69
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release + Dexmethylphenidate 6.25 mg Tablet + Dexmethylphenidate 40 Mg Oral Capsule, Extended Release + Dexmethylphenidate 50 mg TabletPhase 1/2
33
DexmethylphenidatePhase 1
25